title: Epidoxorubicin plus ifosfamide in advanced and/or metastatic soft-tissue sarcomas.
abstract: We undertook this phase II study to evaluate the efficacy and toxicity of epidoxorubicin and ifosfamide in the treatment of locally advanced and/or metastatic soft-tissue sarcomas. We used escalating doses of epidoxorubicin (from 60 to 75 mg/m2) on day 1 and 1.2 g/m2 ifosfamide on days 1-5. Chemotherapy courses were repeated every 3-4 weeks. A total of 16 patients--13 who had not previously been treated and 3 who had undergone prior therapy with anthracyclines--entered the study. In all, 15 patients were evaluable for response and 16, for toxicity. At least two courses of chemotherapy were given. A complete remission (CR) was seen in 1 patient, a partial remission (PR) in 5, and a minor response (MR) in 1, for an objective response rate (CR + PR) of 40% (6/15); this value reached 50% in non-pretreated patients (6/12). Stable disease (SD) was observed in 40% (6/15) of patients. The relative dose intensity of epidoxorubicin ranged from 10 to 23.3 mg/m2 (median, 16.6 mg/m2). The time to objective response ranged from 4 to 12 weeks (median, 8.5 weeks). The duration of response was 4 months for the single CR, and that for the five PRs was 6+ months (range, 4-18 months). Toxicity was evaluated according to WHO criteria in 16 patients; it was mild and consisted mainly of alopecia, nausea and vomiting, and leucopenia. In only three patients did we observe grade 3 leucopenia. In one case an ifosfamide-associated encephalopathy occurred, but it regressed after 24 h. Neither chronic nor acute cardiac toxicity was reported. In this preliminary analysis, the response rate obtained with the combination of epidoxorubicin and ifosfamide was encouraging and the toxicity was acceptable.
authors.affiliation: Istituto Nazionale per la Ricerca sul Cancro, Genova, Italia.
authors.forename: S
authors.initials: S
authors.lastname: Toma
authors.forename: T
authors.initials: T
authors.lastname: Coialbu
authors.forename: L
authors.initials: L
authors.lastname: Biassoni
authors.forename: U
authors.initials: U
authors.lastname: Folco
authors.forename: C
authors.initials: C
authors.lastname: Gatti
authors.forename: G
authors.initials: G
authors.lastname: Canavese
authors.forename: A
authors.initials: A
authors.lastname: Giacchero
authors.forename: R
authors.initials: R
authors.lastname: Rosso
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D004341:Drug Evaluation; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007069:Ifosfamide / Q000009:adverse effects / Q000627:therapeutic use; D015080:Mesna / Q000008:administration & dosage; D008775:Methylprednisolone / Q000008:administration & dosage; D008787:Metoclopramide / Q000008:administration & dosage; D008875:Middle Aged; D012983:Soft Tissue Neoplasms / Q000150:complications / Q000188:drug therapy*; D013997:Time Factors
chemical_list: D015251:Epirubicin; D004317:Doxorubicin; D008787:Metoclopramide; D015080:Mesna; D007069:Ifosfamide; D008775:Methylprednisolone